40 recruiting, 23 active not recruiting, 5 not yet recruiting, 3 suspended. 73 Phase 1, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 73 | Recruiting 40, Active not recruiting 23, Not yet recruiting 5, Suspended 3, Withdrawn 2 |
| Phase 2 | 18 | Recruiting 9, Active not recruiting 7, Not yet recruiting 1, Suspended 1 |
Follow Echocardiography Test: new trials by email Literature Review of Echocardiography Test trials Research Report on Echocardiography Test
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Asciminib, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-12-17 | 2026-10-19 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-10-15 | 2026-09-17 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | City of Hope Medical Center | 24 | 2026-05-26 | 2026-10-23 |
| Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 26 | 2026-05-13 | 2026-10-16 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-04-01 | 2026-05-15 | |
| Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine - Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-01-16 | 2026-09-01 |
Showing 20 of 73. Sign in to see all of them.
Leukemia, Myeloid, Acute (15) · Neoplasm Metastasis (12) · Myelodysplastic Syndromes (6) · Lung Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (3) · Fallopian Tube Neoplasms (3) · Leukemia, Biphenotypic, Acute (3) · Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, T-Cell (3) · Melanoma (3) · Burkitt Lymphoma (2) · Carcinosarcoma (2) · Colorectal Neoplasms (2)
National Cancer Institute (NCI) (37) · Fred Hutchinson Cancer Center (10) · City of Hope Medical Center (8) · Children's Oncology Group (4) · Ohio State University Comprehensive Cancer Center (3) · Mayo Clinic (2) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · Jennifer Saultz (1) · Jonsson Comprehensive Cancer Center (1) · Joshua Palmer (1) · Uma Borate (1) · University of Washington (1)
United States (70) · Canada (4) · Australia (2)
Amandeep Salhotra (2) · Ibrahim Aldoss (2) · Joyce F Liu (2) · Rosa Nadal Rios, MD, PhD (2) · Timothy A Yap (2) · A P Chen (1) · Adam J Esbenshade (1) · Alexandra M Stevens (1) · Alexandre V. Hirayama, MD (1) · Alvaro J Alencar (1) · Amanda Blackmon (1) · Amy C. Degnim, M.D. (1) · Andrea B Apolo (1) · Andreas N Saltos (1) · Andrew Davis (1)
PMID 23810467, PMID 25218906, PMID 32915679, PMID 35031545, PMID 35175355, PMID 36521030, PMID 36898933, PMID 37185961, PMID 37597578, PMID 38954785, PMID 40226119, PMID 40611889, PMID 40721981, PMID 40802906, PMID 40873341, PMID 42007254, PMID 42013378, PMID 42101296, PMID 42500906
P30CA033572 (8), UM1CA186709 (7), UM1CA186688 (6), UM1CA186689 (6), UM1CA228823 (5), UM1CA186704 (4), UM1CA186717 (4), UM1CA186644 (3), U01CA062490 (2), U10CA180886 (2), UM1CA186691 (2), UM1CA186716 (2), ZIABC011078 (2), N01CM00071 (1), P01CA018029 (1)